NZ552576A - Salt adjuvant-containing gel-forming free flowing compositions in a powder form for transdermal delivery from a needless syringe - Google Patents

Salt adjuvant-containing gel-forming free flowing compositions in a powder form for transdermal delivery from a needless syringe

Info

Publication number
NZ552576A
NZ552576A NZ552576A NZ55257601A NZ552576A NZ 552576 A NZ552576 A NZ 552576A NZ 552576 A NZ552576 A NZ 552576A NZ 55257601 A NZ55257601 A NZ 55257601A NZ 552576 A NZ552576 A NZ 552576A
Authority
NZ
New Zealand
Prior art keywords
powder
weight
process according
salt
gel
Prior art date
Application number
NZ552576A
Other languages
English (en)
Inventor
Yuh-Fun Maa
Lu Zhao
Steven Joseph Prestrelski
Original Assignee
Powderject Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Vaccines Inc filed Critical Powderject Vaccines Inc
Publication of NZ552576A publication Critical patent/NZ552576A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
NZ552576A 2000-06-08 2001-06-08 Salt adjuvant-containing gel-forming free flowing compositions in a powder form for transdermal delivery from a needless syringe NZ552576A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59077700A 2000-06-08 2000-06-08
US21058100P 2000-06-08 2000-06-08

Publications (1)

Publication Number Publication Date
NZ552576A true NZ552576A (en) 2008-06-30

Family

ID=26905296

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ552576A NZ552576A (en) 2000-06-08 2001-06-08 Salt adjuvant-containing gel-forming free flowing compositions in a powder form for transdermal delivery from a needless syringe
NZ523103A NZ523103A (en) 2000-06-08 2001-06-08 Salt adjuvant-containing vaccine freeze-dried compositions in a powder form for transdermal delivery from a needless syringe

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ523103A NZ523103A (en) 2000-06-08 2001-06-08 Salt adjuvant-containing vaccine freeze-dried compositions in a powder form for transdermal delivery from a needless syringe

Country Status (11)

Country Link
EP (1) EP1289494A2 (de)
JP (1) JP2003535119A (de)
KR (1) KR20030020294A (de)
CN (1) CN1438874A (de)
AU (1) AU2001275371B9 (de)
BR (1) BR0111494A (de)
CA (1) CA2412197A1 (de)
IL (1) IL153241A0 (de)
MX (1) MXPA02012039A (de)
NZ (2) NZ552576A (de)
WO (1) WO2001093829A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2449593A1 (en) * 2001-06-08 2002-12-19 Powderject Vaccines, Inc. Spray freeze-dried compositions
CN1607941A (zh) * 2001-11-19 2005-04-20 贝克顿迪肯森公司 粒状药物组合物
US7923029B2 (en) 2002-04-11 2011-04-12 Medimmune Llc Spray freeze dry of compositions for pulmonary administration
DE10339197A1 (de) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
TW200626177A (en) * 2004-09-28 2006-08-01 Alza Corp Method and formulation for stabilizing alum-adsorbed vaccines
EP1904290A4 (de) * 2005-06-27 2013-12-18 Applied Thin Films Inc Mikrokügelchen auf aluminiumphosphatbasis
EP1933867A1 (de) 2005-10-04 2008-06-25 Alk-Abello A/S Feste impfstoff-formulierung
EP1945249A2 (de) * 2005-11-01 2008-07-23 Novartis AG Zusammensetzungen mit an calciumphosphat adsorbierten antigenen
US20080226729A1 (en) * 2006-09-08 2008-09-18 Becton, Dickinson And Company Stable powder formulations of alum-adsorbed vaccines
JP2010505883A (ja) 2006-10-12 2010-02-25 ザ ユニバーシティー オブ クイーンズランド 免疫応答を調節するための組成物および方法
CA2681567C (en) 2007-03-22 2016-07-19 The Regents Of The University Of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
MX2010001054A (es) * 2007-07-26 2010-04-21 Sanofi Pasteur Ltd Composiciones adyuvantes antigenicas y metodos.
ES2615390T3 (es) 2008-03-05 2017-06-06 Sanofi Pasteur Proceso para estabilizar una composición de vacuna que contiene adyuvante
AU2009299615B2 (en) 2008-10-02 2015-07-16 Pharmathene Inc. Anthrax vaccine formulation and uses thereof
BR112012025047A2 (pt) 2010-03-31 2016-06-21 Stabilitech Ltd formulações líquidas estabilizadas
EP2552410B1 (de) * 2010-03-31 2018-10-24 Stabilitech Biopharma Ltd Verfahren zur konservierung von alaun-adjuvantien und imfpstoffe mit alaun-adjuvantien
HUE026885T2 (en) 2010-03-31 2016-08-29 Stabilitech Ltd Stabilize virus fragments
BR112013010926A2 (pt) 2010-11-01 2016-08-23 Univ Technology Sidney agentes imunomoduladores e seus usos
MX349294B (es) 2010-12-02 2017-07-21 Oncolytics Biotech Inc Formulaciones virales liofilizadas.
AU2011336413B2 (en) 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Liquid viral formulations
CN102133396B (zh) * 2011-03-16 2013-10-16 中国人民解放军第三〇二医院 一种疫苗注射剂及其制备方法
US12447127B2 (en) 2011-05-17 2025-10-21 The Regents Of The University Of Colorado, A Body Corporate Thermostable vaccine compositions and methods of preparing the same
US20130309273A1 (en) 2012-05-17 2013-11-21 Kimberly Hassett Thermostable Vaccine Compositions and Methods of Preparing Same
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
WO2013133702A1 (en) * 2012-03-05 2013-09-12 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Methods and compositions for stabilizing dried biological materials
KR101441539B1 (ko) * 2013-04-01 2014-09-18 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 흡습성이 개선된 접착제 조성물 및 이의 제조방법
CN103641886B (zh) * 2013-11-26 2015-07-29 精晶药业股份有限公司 一种丙谷二肽的精制方法
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
GB202400295D0 (en) * 2024-01-09 2024-02-21 Stablepharma Ltd Hypertonic thermostable vaccine compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
HU188847B (en) * 1983-02-22 1986-05-28 Human Oltoanyagtermeloe Es Kutato Intezet,Hu Process for producing liophylized combined vaccines
JPS6013718A (ja) * 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst B型肝炎ワクチン
JP2749449B2 (ja) * 1992-12-28 1998-05-13 ユー、シイ−チャン 不揮発性半導体メモリセル
EP0678035B9 (de) * 1993-01-08 2006-12-13 Csl Limited Impfstoffpräparate
TW404844B (en) * 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
RU2096042C1 (ru) * 1996-11-06 1997-11-20 Виктор Иванович Ситьков Способ получения поливалентной вакцины против лептоспироза животных
NZ504894A (en) * 1997-12-02 2002-12-20 Powderject Vaccines Inc Crystalline vaccine and adjuvant compositions jointly and separately administered to animals using a transdermal or transmucosally delivery technique

Also Published As

Publication number Publication date
NZ523103A (en) 2005-08-26
CA2412197A1 (en) 2001-12-13
AU2001275371B9 (en) 2007-06-07
MXPA02012039A (es) 2003-06-06
WO2001093829A3 (en) 2002-06-13
IL153241A0 (en) 2003-07-06
AU2001275371B2 (en) 2006-12-21
CN1438874A (zh) 2003-08-27
JP2003535119A (ja) 2003-11-25
BR0111494A (pt) 2004-01-13
EP1289494A2 (de) 2003-03-12
KR20030020294A (ko) 2003-03-08
WO2001093829A2 (en) 2001-12-13
AU7537101A (en) 2001-12-17

Similar Documents

Publication Publication Date Title
AU2001275371B9 (en) Powder compositions
US20020120228A1 (en) Powder compositions
US7229645B2 (en) Spray freeze-dried compositions
EP1146861B1 (de) Hydrogelpartikel formulierungen
US20100173005A1 (en) Microparticle formulations for sustained-release of bioactive compounds
JP2001524533A (ja) 粒子状ワクチン組成物の経皮的送達
EP1592443A1 (de) Verbesserte anthraximpfstoffe und abgabeverfahren
AU770235B2 (en) Delivery of microparticle formulations using needleless syringe device for sustained-release of bioactive compounds
US20020051821A1 (en) Aliginate particle formulation
US20040213798A1 (en) Spray-dried alum compositions
US20050191361A1 (en) Hydrogel particle formation
AU2001275371A1 (en) Powder compositions
Ziegler Needle-free delivery of powdered protein vaccines: a new and rapidly developing technique
EP1399132A1 (de) Herstellung von harten und dichten partikeln
Pietsch Spray-freeze drying process development for the production of solid powder particles for a needle-free injection

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed